FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3008894446> ?p ?o ?g. }

• W3008894446 endingPage "516" @default.
• W3008894446 startingPage "507" @default.
• W3008894446 abstract "Molecular and immunohistochemistry-based profiling of prostatic adenocarcinoma has revealed frequent Androgen Receptor (AR) gene and protein alterations in metastatic disease. This includes an AR-null non-neuroendocrine phenotype of metastatic castrate resistant prostate cancer which may be less sensitive to androgen receptor signaling inhibitors. This AR-null non-neuroendocrine phenotype is thought to be associated with TP53 and RB1 alterations. Herein, we have correlated molecular profiling of metastatic castrate resistant prostate cancer with AR/P53/RB immunohistochemistry and relevant clinical correlates. Twenty-seven cases of metastatic castrate resistant prostate cancer were evaluated using histopathologic examination to rule out neuroendocrine differentiation. A combination of a hybridization exon-capture next-generation sequencing-based assay (n = 26), fluorescence in situ hybridization for AR copy number status (n = 16), and immunohistochemistry for AR (n = 27), P53 (n = 24) and RB (n = 25) was used to profile these cases. Of 27 metastatic castrate resistant prostate cancer cases, 17 had AR amplification and showed positive nuclear expression of AR by immunohistochemistry. Nine cases lacked AR copy number alterations using next-generation sequencing/fluorescence in situ hybridization. A subset of these metastatic castrate resistant prostate cancer cases demonstrated the AR-null phenotype by immunohistochemistry (five cases and one additional case where next-generation sequencing failed). Common co-alterations in these cases involved the TP53, RB1, and PTEN genes and all these patients received prior therapy with androgen receptor signaling inhibitors (abiraterone and/or enzalutamide). Our study suggests that AR immunohistochemistry may distinguish AR-null from AR-expressing cases in the metastatic setting. AR-null status informs clinical decision-making regarding continuation of therapy with androgen receptor signaling inhibitors and consideration of other treatment options. This might be a relevant and cost-effective diagnostic strategy when there is limited access and/or limited tumor material for molecular testing." @default.
• W3008894446 created "2020-03-06" @default.
• W3008894446 creator A5003119579 @default.
• W3008894446 creator A5010079764 @default.
• W3008894446 creator A5010536553 @default.
• W3008894446 creator A5017288060 @default.
• W3008894446 creator A5020234995 @default.
• W3008894446 creator A5022477189 @default.
• W3008894446 creator A5024437929 @default.
• W3008894446 creator A5028587910 @default.
• W3008894446 creator A5046345178 @default.
• W3008894446 creator A5047795118 @default.
• W3008894446 creator A5048060846 @default.
• W3008894446 creator A5062426672 @default.
• W3008894446 creator A5072850546 @default.
• W3008894446 creator A5077413102 @default.
• W3008894446 creator A5083028392 @default.
• W3008894446 creator A5089185942 @default.
• W3008894446 date "2020-02-24" @default.
• W3008894446 modified "2023-10-10" @default.
• W3008894446 title "Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer" @default.
• W3008894446 cites W1192724814 @default.
• W3008894446 cites W1913797671 @default.
• W3008894446 cites W1985143543 @default.
• W3008894446 cites W2017437369 @default.
• W3008894446 cites W2023400202 @default.
• W3008894446 cites W2033737920 @default.
• W3008894446 cites W2039511031 @default.
• W3008894446 cites W2103959341 @default.
• W3008894446 cites W2114843025 @default.
• W3008894446 cites W2118055719 @default.
• W3008894446 cites W2130875528 @default.
• W3008894446 cites W2137974207 @default.
• W3008894446 cites W2156923287 @default.
• W3008894446 cites W2181283187 @default.
• W3008894446 cites W223909586 @default.
• W3008894446 cites W2278392405 @default.
• W3008894446 cites W2561005826 @default.
• W3008894446 cites W2564702165 @default.
• W3008894446 cites W2611922828 @default.
• W3008894446 cites W2613362156 @default.
• W3008894446 cites W2620706965 @default.
• W3008894446 cites W2727045138 @default.
• W3008894446 cites W2749326421 @default.
• W3008894446 cites W2762381618 @default.
• W3008894446 cites W2767214731 @default.
• W3008894446 cites W2788051020 @default.
• W3008894446 cites W2789730857 @default.
• W3008894446 cites W2808687910 @default.
• W3008894446 cites W2841858285 @default.
• W3008894446 cites W2894341066 @default.
• W3008894446 cites W2903943172 @default.
• W3008894446 cites W2904249129 @default.
• W3008894446 cites W2937000547 @default.
• W3008894446 cites W2944403040 @default.
• W3008894446 doi "https://doi.org/10.1038/s41391-020-0214-6" @default.
• W3008894446 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7433029" @default.
• W3008894446 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32094488" @default.
• W3008894446 hasPublicationYear "2020" @default.
• W3008894446 type Work @default.
• W3008894446 sameAs 3008894446 @default.
• W3008894446 citedByCount "10" @default.
• W3008894446 countsByYear W30088944462021 @default.
• W3008894446 countsByYear W30088944462022 @default.
• W3008894446 countsByYear W30088944462023 @default.
• W3008894446 crossrefType "journal-article" @default.
• W3008894446 hasAuthorship W3008894446A5003119579 @default.
• W3008894446 hasAuthorship W3008894446A5010079764 @default.
• W3008894446 hasAuthorship W3008894446A5010536553 @default.
• W3008894446 hasAuthorship W3008894446A5017288060 @default.
• W3008894446 hasAuthorship W3008894446A5020234995 @default.
• W3008894446 hasAuthorship W3008894446A5022477189 @default.
• W3008894446 hasAuthorship W3008894446A5024437929 @default.
• W3008894446 hasAuthorship W3008894446A5028587910 @default.
• W3008894446 hasAuthorship W3008894446A5046345178 @default.
• W3008894446 hasAuthorship W3008894446A5047795118 @default.
• W3008894446 hasAuthorship W3008894446A5048060846 @default.
• W3008894446 hasAuthorship W3008894446A5062426672 @default.
• W3008894446 hasAuthorship W3008894446A5072850546 @default.
• W3008894446 hasAuthorship W3008894446A5077413102 @default.
• W3008894446 hasAuthorship W3008894446A5083028392 @default.
• W3008894446 hasAuthorship W3008894446A5089185942 @default.
• W3008894446 hasBestOaLocation W30088944462 @default.
• W3008894446 hasConcept C121608353 @default.
• W3008894446 hasConcept C126322002 @default.
• W3008894446 hasConcept C142724271 @default.
• W3008894446 hasConcept C204232928 @default.
• W3008894446 hasConcept C2776235491 @default.
• W3008894446 hasConcept C2776551883 @default.
• W3008894446 hasConcept C2780192828 @default.
• W3008894446 hasConcept C2780341458 @default.
• W3008894446 hasConcept C2781182431 @default.
• W3008894446 hasConcept C502942594 @default.
• W3008894446 hasConcept C61367390 @default.
• W3008894446 hasConcept C71924100 @default.
• W3008894446 hasConceptScore W3008894446C121608353 @default.
• W3008894446 hasConceptScore W3008894446C126322002 @default.
• W3008894446 hasConceptScore W3008894446C142724271 @default.

• next